Nucleocapsid-specific humoral responses improve the control of SARS-CoV-2
Summary The spike protein of SARS-CoV-2 is a critical antigen present in all approved SARS-CoV-2 vaccines. This surface viral protein is also the target for all monoclonal antibody therapies, but it is unclear whether antibodies targeting other viral proteins can also improve protection against COVID-19. Here, we interrogate whether nucleocapsid-specific antibodies can improve protection against SARS-CoV-2. We first immunized mice with a nucleocapsid-based vaccine, and then transferred sera from these mice into naïve mice. On the next day, the recipient mice were challenged intranasally with SARS-CoV-2 to evaluate whether nucleocapsid-specific humoral responses affect viral control. Interestingly, mice that received nucleocapsid-specific sera exhibited enhanced control of a SARS-CoV-2 infection. These findings provide the first demonstration that humoral responses specific to an internal coronavirus protein can help clear infection, warranting the inclusion of other viral antigens in next-generation SARS-CoV-2 vaccines and providing a rationale for the clinical evaluation of nucleocapsid-specific monoclonals to treat COVID-19.Highlights A SARS-CoV-2 nucleocapsid vaccine elicits robust nucleocapsid-specific antibody responses.This nucleocapsid vaccine generates memory B cells (MBC).Nucleocapsid-specific humoral responses do not prevent SARS-CoV-2 infection.Nucleocapsid-specific humoral responses help control a SARS-CoV-2 infection..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
bioRxiv.org - (2022) vom: 12. März Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dangi, Tanushree [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.1101/2022.03.09.483635 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI03546738X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI03546738X | ||
| 003 | DE-627 | ||
| 005 | 20230429082840.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220313s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2022.03.09.483635 |2 doi | |
| 035 | |a (DE-627)XBI03546738X | ||
| 035 | |a (biorXiv)10.1101/2022.03.09.483635 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Dangi, Tanushree |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nucleocapsid-specific humoral responses improve the control of SARS-CoV-2 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Summary The spike protein of SARS-CoV-2 is a critical antigen present in all approved SARS-CoV-2 vaccines. This surface viral protein is also the target for all monoclonal antibody therapies, but it is unclear whether antibodies targeting other viral proteins can also improve protection against COVID-19. Here, we interrogate whether nucleocapsid-specific antibodies can improve protection against SARS-CoV-2. We first immunized mice with a nucleocapsid-based vaccine, and then transferred sera from these mice into naïve mice. On the next day, the recipient mice were challenged intranasally with SARS-CoV-2 to evaluate whether nucleocapsid-specific humoral responses affect viral control. Interestingly, mice that received nucleocapsid-specific sera exhibited enhanced control of a SARS-CoV-2 infection. These findings provide the first demonstration that humoral responses specific to an internal coronavirus protein can help clear infection, warranting the inclusion of other viral antigens in next-generation SARS-CoV-2 vaccines and providing a rationale for the clinical evaluation of nucleocapsid-specific monoclonals to treat COVID-19.Highlights A SARS-CoV-2 nucleocapsid vaccine elicits robust nucleocapsid-specific antibody responses.This nucleocapsid vaccine generates memory B cells (MBC).Nucleocapsid-specific humoral responses do not prevent SARS-CoV-2 infection.Nucleocapsid-specific humoral responses help control a SARS-CoV-2 infection. | ||
| 700 | 1 | |a Sanchez, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Mincheol |e verfasserin |4 aut | |
| 700 | 1 | |a Class, Jacob |e verfasserin |4 aut | |
| 700 | 1 | |a Richner, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Richner, Justin M. |e verfasserin |4 aut | |
| 700 | 1 | |a Penaloza-MacMaster, Pablo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2022) vom: 12. März |
| 773 | 1 | 8 | |g year:2022 |g day:12 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2022.03.09.483635 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 12 |c 03 | ||
| 953 | |2 045F |a 570 | ||